Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,448
  • Shares Outstanding, K 98,770
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -145,540 K
  • 60-Month Beta 1.29
  • Price/Sales 11.25
  • Price/Cash Flow N/A
  • Price/Book 0.30
Trade ADVM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.57
  • Most Recent Earnings -0.38 on 05/12/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 366.44% ( -16.33%)
  • Historical Volatility 63.80%
  • IV Percentile 91%
  • IV Rank 40.71%
  • IV High 820.64% on 05/16/22
  • IV Low 54.59% on 08/11/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 26,017
  • Open Int (30-Day) 26,761

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.39
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +15.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7954 +7.49%
on 05/16/22
1.2400 -31.05%
on 04/21/22
-0.2850 (-25.00%)
since 04/20/22
3-Month
0.7954 +7.49%
on 05/16/22
1.5100 -43.38%
on 03/25/22
-0.5150 (-37.59%)
since 02/18/22
52-Week
0.7954 +7.49%
on 05/16/22
3.8600 -77.85%
on 06/25/21
-2.6650 (-75.71%)
since 05/20/21

Most Recent Stories

More News
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 0.8550 (+0.08%)
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 0.8550 (+0.08%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 0.8550 (+0.08%)
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting

- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean...

ADVM : 0.8550 (+0.08%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022

Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD...

ADVM : 0.8550 (+0.08%)
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

VYGR : 6.36 (-0.31%)
ADVM : 0.8550 (+0.08%)
TRVI : 2.25 (+1.35%)
AXLA : 1.7400 (+2.35%)
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA

Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of...

ADVM : 0.8550 (+0.08%)
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 0.8550 (+0.08%)
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors

REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 0.8550 (+0.08%)
Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADVM : 0.8550 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 0.9700
2nd Resistance Point 0.9300
1st Resistance Point 0.8925
Last Price 0.8550
1st Support Level 0.8150
2nd Support Level 0.7750
3rd Support Level 0.7375

See More

52-Week High 3.8600
Fibonacci 61.8% 2.6893
Fibonacci 50% 2.3277
Fibonacci 38.2% 1.9661
Last Price 0.8550
52-Week Low 0.7954

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar